Newsroom
Sorted by: Latest
-
The Manitowoc Company to Participate at Investor Conferences on June 9-10, 2026
MILWAUKEE--(BUSINESS WIRE)--The Manitowoc Company, Inc. (NYSE: MTW) announced today that Executive Vice President and Chief Financial Officer, Brian P. Regan, and Senior Vice President, Marketing and Investor Relations, Ion M. Warner, will attend the following investor conferences: Tuesday, June 9, 2026 at the Wells Fargo Investor Conference in Chicago, Illinois. Wednesday, June 10, 2026 at the East Coast IDEAS Conference in New York City. Manitowoc’s presentation is scheduled at 2:00 p.m. ET (...
-
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath’s perc...
-
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics will present at 2026 Jefferies Global Healthcare Conference...
-
Transcat Reports Strong Fiscal Fourth Quarter 2026 Financial Results with Continued High Single-Digit Service Organic Revenue* Growth
ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Reports Strong Fiscal Fourth Quarter 2026 Financial Results with Continued High Single-Digit Service Organic Revenue* Growth...
-
VTEX Announces the Results of its 2026 Annual General Meeting of Shareholders
NEW YORK--(BUSINESS WIRE)--VTEX (NYSE: VTEX), the backbone for connected commerce, announced today that the following matters were approved in its annual general meeting of shareholders (“AGM”) held on May 26, 2026: Proposal No. 1: the ratification and approval of financial statements and the auditor’s report for the fiscal year ended December 31, 2025. Proposal No. 2: the appointment of PricewaterhouseCoopers Auditores Independentes Ltda. as the Company’s independent registered public accounti...
-
H.B. Fuller Issues Statement Regarding Value Creation Strategy
NEW YORK--(BUSINESS WIRE)--H.B. Fuller (NYSE: FUL) today issued the following statement: “Our Board and management team value the feedback of all shareholders and regularly engage with and listen to a diverse range of perspectives shared with the Company, as we have with Ancora. The H.B. Fuller management team is successfully executing on our stated strategy to reposition the business into a faster-growing and higher margin specialty adhesives player. Our team’s strong operational execution com...
-
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an inducement grant (the “Inducement Grant”) was made to Anthony Catalano in connection with the commencement of his employment as the Chief Operating Officer of the Company. The Inducement Grant consists of restricted stock units (“RSUs”) covering 141...
-
Octave Bioscience Accelerates Precision Neurology Momentum, Appoints Zachary Fernandes as VP of Business Development to Scale Strategic Partnerships
MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker-driven solutions for multiple sclerosis, Parkinson's and other neurodegenerative diseases, today announced the appointment of Zachary Fernandes as Vice President, Business Development. He will lead Octave’s partnership strategy focused on driving durable revenue growth through transformative, strategic collaborations across the life sciences ecosystem. Mr. Fernandes h...
-
Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from its first-in-human Phase 1 study of MAR002 will be highlighted in an oral presentation at the 2026 Annual Meeting of the Endocrine Society (ENDO), being held from June 13-16 in Chicago, IL. MAR002 is a first-in-class alloster...
-
Expedia Group to Participate in Evercore’s 2026 Global TMT Conference
SEATTLE--(BUSINESS WIRE)--Expedia Group (NASDAQ: EXPE) will participate in Evercore’s 2026 Global TMT Conference. Ariane Gorin, Chief Executive Officer, will participate in a fireside chat on Tuesday, June 2, 2026 at 10:00 am PT / 1:00 pm ET. A live webcast of the session will be available at ir.expediagroup.com. A replay of the webcast will be accessible for 3 months. About Expedia Group Expedia Group, Inc. (NASDAQ: EXPE) is the global travel marketplace with one purpose: to help travelers exp...